Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INVERSINE vs DEL-VI-A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors, blocking ganglionic transmission in both sympathetic and parasympathetic ganglia.
Delvi-ā is a monoclonal antibody that binds to the interleukin-23 (IL-23) p19 subunit, inhibiting IL-23-mediated signaling and reducing inflammatory cytokine production.
Management of moderately severe to severe essential hypertension,Unresponsive hypertension to other agents
Moderate to severe plaque psoriasis,Psoriatic arthritis,Crohn's disease
Initial: 2.5 mg orally twice daily; increase by 2.5-5 mg every 2-3 days until blood pressure controlled; usual maintenance: 10-75 mg/day in 2-4 divided doses; max single dose: 25 mg; max daily dose: 200 mg.
10 mg orally once daily, taken with or without food.
3-5 hours in patients with normal renal function; may be prolonged in renal impairment (up to 12-24 hours in severe cases).
Terminal elimination half-life is 12-15 hours in patients with normal renal function. Half-life is prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and requires dose adjustment.
Primarily hepatic metabolism (unknown specific enzymes); eliminated renally with unchanged drug and metabolites.
Metabolized via catabolic pathways into small peptides and amino acids.
Primarily renal (about 90% as unchanged drug), with minor biliary/fecal elimination (<10%).
Renal excretion of unchanged drug accounts for 60-70% of elimination, with 20-30% excreted as glucuronide conjugate. Biliary/fecal excretion accounts for approximately 10%.
~50% bound to plasma proteins (mainly albumin).
Approximately 85% bound to serum albumin.
Approximately 1 L/kg, indicating extensive extravascular distribution.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in obesity (up to 1.2 L/kg) suggests extensive tissue binding.
Oral: 50-75% (due to first-pass metabolism).
Oral bioavailability is 60-70% due to first-pass metabolism. No significant food effect observed.
GFR 30-60 m L/min: reduce dose by 50%; GFR 10-29 m L/min: reduce dose by 75%; GFR <10 m L/min: avoid use.
Cr Cl 30-89 m L/min: no adjustment; Cr Cl 15-29 m L/min: 5 mg once daily; Cr Cl <15 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not approved for patients <18 years. Safety and efficacy not established.
Start at 2.5 mg once daily; increase slowly; monitor for orthostatic hypotension and syncope.
No specific dose adjustment; use caution due to age-related renal impairment and potential for orthostatic hypotension.
None.
None.
May cause orthostatic hypotension, syncope, and falls. Use with caution in patients with cerebrovascular insufficiency, renal impairment, or recent myocardial infarction. Discontinue if symptoms of paralytic ileus occur.
Increased risk of infections including tuberculosis,Hypersensitivity reactions,Hepatic transaminase elevations
Coronary insufficiency, recent myocardial infarction, pyloric stenosis, glaucoma, uremia, and patients receiving concurrent antihypertensive therapy with ganglionic blocking agents.
Known hypersensitivity to delvi-ā or any excipients,Active serious infections
Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats) as mecamylamine may potentiate pressor effects. Limit alcohol consumption due to additive hypotensive effects. High-sodium foods may counteract antihypertensive effect; follow a low-sodium diet as recommended.
Take with meals to reduce gastrointestinal side effects. Avoid high-fat meals as they may decrease delavirdine absorption. Grapefruit juice may increase delavirdine levels; avoid concurrent use. No other significant food interactions known.
Category C. First trimester: No adequate human studies; animal studies show embryotoxicity. Second/third trimester: Potential for meconium ileus, neonatal hypotension. Avoid in pregnancy.
DEL-VI-A is contraindicated in all trimesters due to documented teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Second and third trimester exposure linked to fetal growth restriction and oligohydramnios.
Excreted in breast milk. M/P ratio unknown. Discontinue breastfeeding due to potential for serious adverse effects in infant.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended. M/P ratio not available.
No established dosing guidelines for pregnancy; increased clearance suggests need for dose escalation, but contraindicated due to risks.
No safe dose established; drug is contraindicated in pregnancy. Due to altered pharmacokinetics (increased volume of distribution, enhanced clearance), if inadvertent exposure occurs, no dose adjustment can be recommended as any exposure poses fetal risk.
INVERSINE (mecamylamine) is a noncompetitive nicotinic acetylcholine receptor antagonist used primarily for its ganglionic blocking effects in severe hypertension. Due to its narrow therapeutic index and significant side effects including orthostatic hypotension, constipation, and urinary retention, it is rarely used today. Monitor for paralytic ileus and bladder distention. Dosage must be titrated carefully based on standing blood pressure. Contraindicated in patients with coronary insufficiency, pyloric stenosis, or recent myocardial infarction.
DEL-VI-A is a combination of delavirdine and vitamin A. Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1. Monitor for hepatotoxicity, especially in patients with hepatitis B/C coinfection or pre-existing liver disease. Administer with food to reduce GI upset. Vitamin A component may cause hypervitaminosis A if taken with other supplements. Use with caution in patients with renal impairment; no dose adjustment needed for mild-moderate, but avoid in severe (Cr Cl <30 m L/min).
Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Rise slowly from sitting or lying positions to avoid dizziness from low blood pressure.,Report any constipation, difficulty urinating, or blurred vision to your healthcare provider immediately.,Avoid alcohol and other medications that lower blood pressure without medical advice.,Do not drive or operate heavy machinery if you experience dizziness or blurred vision.,Maintain adequate fluid intake unless otherwise directed by your doctor.
Take DEL-VI-A exactly as prescribed, typically three times daily with food.,Do not skip doses or stop taking without consulting your doctor, as this may lead to drug resistance.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, pale stools, or persistent nausea.,Avoid taking additional vitamin A supplements or multivitamins containing vitamin A to prevent toxicity.,DEL-VI-A does not cure HIV or prevent transmission; continue safe sex practices.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INVERSINE vs DEL-VI-A, answered by our medical review team.
INVERSINE is a Ganglionic Blocker Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors, blocking ganglionic transmission in both sympathetic and parasympathetic ganglia.. DEL-VI-A is a Vitamin A supplement that works by Delvi-ā is a monoclonal antibody that binds to the interleukin-23 (IL-23) p19 subunit, inhibiting IL-23-mediated signaling and reducing inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INVERSINE and DEL-VI-A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INVERSINE is: Initial: 2.5 mg orally twice daily; increase by 2.5-5 mg every 2-3 days until blood pressure controlled; usual maintenance: 10-75 mg/day in 2-4 divided doses; max single dose: 25 mg; max daily dose: 200 mg.. The standard adult dose of DEL-VI-A is: 10 mg orally once daily, taken with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INVERSINE and DEL-VI-A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INVERSINE is classified as Category C. Category C. First trimester: No adequate human studies; animal studies show embryotoxicity. Second/third trimester: Potential for meconium ileus, neonatal hypotension. Avoid in pre. DEL-VI-A is classified as Category C. DEL-VI-A is contraindicated in all trimesters due to documented teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.